04:24 PM EDT, 08/12/2026 (MT Newswires) -- Kura Oncology ( KURA ) reported a Q2 diluted loss of $0.77 per share, compared with a loss of $0.75 a year earlier.

Analysts polled by FactSet expected loss of $0.88.

Revenue for the quarter ended June 30 was $20.9 million, up from $15.3 million a year ago.

Analysts surveyed by FactSet expected $20.2 million.

Kura had $519.0 million in cash, cash equivalents and short-term investments as of June 30.